Recell PDRN 3ml×5: Tissue Regeneration Protocol

Medical Review Status: Verified

Reviewed By: Dr. Sarah Jenkins, MD, Board-Certified Dermatologist | Last Updated: April 2026

Evidence Grade: Level A (Supported by multiple randomized double-blind clinical trials regarding PDRN efficacy).

Polydeoxyribonucleotide (PDRN) operates via the nucleotide salvage pathway. Active DNA fragments specifically bind to A2A adenosine receptors on fibroblast cellular membranes.

Anti-inflammatory action: Downregulates pro-inflammatory cytokines including TNF-α and IL-6.

Angiogenesis & Proliferation: Upregulates Vascular Endothelial Growth Factor (VEGF) and Fibroblast Growth Factor (FGF), accelerating de novo dermal matrix synthesis.

Clinical Efficacy Data

Federal and international medical regulations restrict this device to sale by or on the order of a licensed physician. Strict adherence to aseptic techniques is mandatory.

Contraindications: Administration is strictly prohibited in patients with active autoimmune diseases, known hypersensitivity to salmonid DNA, or active injection-site infections.

Clinical outcomes vary based on patient age, baseline dermal condition, and protocol compliance. The manufacturer assumes no liability for off-label usage or administration by uncertified personnel.